Clinical Trial Detail

NCT ID NCT03631199
Title Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Cisplatin

Paclitaxel

Nab-paclitaxel

Carboplatin

Canakinumab + Pembrolizumab

Pembrolizumab

Pemetrexed Disodium

Age Groups: senior adult

Additional content available in CKB BOOST